Biopreservation Market By Type (Biopreservation Media, Biopreservation Systems, Cryopreservation Solutions), By Application (Cell & Gene Therapy, Regenerative Medicine, Stem Cell Preservation, Tissue Preservation, Vaccines & Biologics Preservation), By End-Use Industry (Pharmaceuticals & Biotechnology, Healthcare, Food & Beverages, Academic & Research Institutes), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Biopreservation Market was valued at USD 5.1 billion in 2024-e and will surpass USD 9.3 billion by 2030; growing at a CAGR of 10.4% during 2025 - 2030.

The biopreservation market is expanding rapidly due to increasing applications in preserving biological materials such as cells, tissues, and organs for therapeutic purposes. As biotechnological advances continue, biopreservation techniques are critical for ensuring the stability and longevity of these biological materials, enabling advancements in regenerative medicine, cell and gene therapies, and organ transplantation. The market is further fueled by the rising demand for vaccines and biologics, where preservation plays a pivotal role in maintaining the efficacy of these complex products.

The continued growth in biotechnology, pharmaceuticals, and healthcare sectors, coupled with the increasing demand for personalized treatments and regenerative therapies, is driving innovation within the biopreservation space. The need for high-quality biopreservation solutions is critical in ensuring that biological materials retain their integrity during storage, transport, and use. As such, biopreservation is poised to become even more integral to modern healthcare and pharmaceutical applications, particularly in areas like cell therapy, regenerative medicine, and biologics production.

Biopreservation Media is the Largest Owing to its Crucial Role in Cell and Gene Therapy

Biopreservation media is the largest subsegment within the biopreservation market, owing to its crucial role in maintaining the viability and functionality of cells and tissues used in therapies such as cell and gene therapy. These media provide the necessary nutrients and environmental conditions to preserve cellular integrity during storage and transport. The increasing prevalence of cell-based therapies and the growing demand for personalized medicine are key factors driving the demand for advanced biopreservation media.

The ongoing developments in gene and cell therapies require specialized preservation solutions to ensure that biological materials retain their therapeutic efficacy. As the demand for regenerative medicine grows, biopreservation media will remain at the forefront of this sector, ensuring the continued viability of the cells and tissues that form the basis for these advanced therapies.

Cell & Gene Therapy is the Largest Owing to Breakthroughs in Personalized Medicine

Cell & gene therapy is the largest application in the biopreservation market, driven by the rapid advancements in personalized medicine. These therapies, which involve the modification of cells or genes to treat various genetic disorders, require precise and efficient biopreservation methods to maintain the quality and efficacy of biological materials. The increasing approval of cell and gene therapies by regulatory authorities and the growing number of clinical trials are boosting the demand for biopreservation solutions.

As the field of cell and gene therapy evolves, new and improved biopreservation techniques are being developed to address the challenges associated with storing and transporting cells. The ability to preserve the integrity of cells during long-term storage is critical to the success of these therapies, making cell and gene therapy the largest application driving the biopreservation market.

Pharmaceuticals & Biotechnology is the Largest Owing to Investment in Biopharmaceuticals

Pharmaceuticals and biotechnology companies represent the largest end-user segment in the biopreservation market. These industries require high-quality biopreservation solutions for the storage and preservation of biologics, vaccines, and cell-based therapies. The rising investment in the development of biopharmaceutical products, including monoclonal antibodies, stem cell therapies, and gene therapies, is a key driver for the demand for biopreservation technologies.

Additionally, pharmaceutical companies involved in vaccine production and biologics manufacturing require biopreservation systems to ensure the stability and efficacy of these sensitive products throughout their supply chains. As demand for biologics continues to increase, pharmaceutical and biotechnology companies will remain the largest end-users of biopreservation technologies.

North America is Largest Owing to Advanced Biopharmaceutical and Healthcare Infrastructure

North America is the largest region in the biopreservation market, primarily due to its advanced healthcare infrastructure and strong presence of biopharmaceutical and biotechnology companies. The region's high level of investment in research and development, particularly in cell-based therapies, regenerative medicine, and vaccine production, supports the growing demand for biopreservation solutions. North America's regulatory environment, which encourages innovation in biopharmaceuticals, further drives the adoption of advanced preservation technologies.

As the region continues to lead in biotechnology and pharmaceuticals, North America will maintain its dominant position in the biopreservation market. The ongoing demand for innovative healthcare solutions and the increasing focus on personalized medicine ensure that biopreservation will remain a critical component of the healthcare and pharmaceutical industries in the region.

Leading Companies and Competitive Landscape

The biopreservation market is characterized by the presence of major players such as Thermo Fisher Scientific, BioLife Solutions, and Sartorius, who are leading the development and commercialization of advanced biopreservation products. These companies provide a range of biopreservation media, systems, and cryopreservation solutions to meet the needs of the growing cell and gene therapy, regenerative medicine, and vaccine industries.

The competitive landscape is marked by a strong focus on innovation, with companies investing in research and development to offer more efficient and scalable preservation solutions. Collaborations and partnerships between biopharmaceutical companies, academic research institutes, and technology providers are becoming increasingly common, as the need for improved biopreservation methods in personalized medicine and cell-based therapies continues to rise. Companies are also expanding their product portfolios through acquisitions and mergers, positioning themselves for growth in a rapidly evolving market.

Recent Developments:

• In January 2025, BioLife Solutions expanded its portfolio of cryopreservation media with a new product designed for long-term stem cell storage.
• In December 2024, Thermo Fisher Scientific acquired a leading biopreservation company, enhancing its capabilities in the healthcare sector.
• In November 2024, Merck KGaA launched a new line of biopreservation solutions aimed at improving vaccine storage in the pharmaceutical industry.
• In October 2024, Cryoport, Inc. secured a partnership with a global biotech firm to provide biopreservation logistics for cell and gene therapies.
• In September 2024, Lonza Group unveiled a new biopreservation technology focused on the preservation of tissues for regenerative medicine applications.

List of Leading Companies:

• BioLife Solutions
• Thermo Fisher Scientific
• Merck KGaA
• GE Healthcare
• Lonza Group
• Vitrolife AB
• Cryoport, Inc.
• Stemcell Technologies
• Fujifilm Irvine Scientific
• Sigma-Aldrich (Merck)
• Chart Industries, Inc.
• Samsung Biologics
• BioCision LLC
• Panasonic Healthcare
• Revivicor Inc.

Report Scope: